10-Q: Leidos Holdings Reports Strong First Quarter 2024 Results Driven by Health and Civil Sector Growth
Quarterly Report
Leidos Holdings, Inc. reported a significant increase in net income and revenue for the first quarter of 2024, driven by strong performance in the Health & Civil sector and overall business growth.
Summary
- Leidos Holdings, Inc. reported a net income of $283 million for the quarter ended March 29, 2024, a substantial increase from $164 million in the same period last year.
- The company's revenue reached $3.975 billion, up from $3.699 billion in the first quarter of 2023.
- Operating income also saw a significant rise, reaching $415 million compared to $265 million in the prior year.
- The Health & Civil segment showed the most significant growth, with a 18.9% increase in revenue and a 96.5% increase in operating income.
- Leidos recorded net bookings of $3.7 billion during the quarter, compared to $3.0 billion in the same period last year.
- The company's total backlog stands at $36.571 billion as of March 29, 2024.
- Approximately 62% of the remaining performance obligations are expected to be recognized over the next 12 months and 78% over the next 24 months.
Sentiment
Score: 8
Explanation: The document presents a very positive outlook with strong financial results, significant growth in key segments, and a healthy backlog. While there are some minor negatives and risks, the overall tone is optimistic and indicates a strong performance by the company.
Positives
- The company experienced a significant increase in net income and revenue.
- The Health & Civil segment demonstrated exceptional growth in both revenue and operating income.
- Leidos secured strong bookings during the quarter, indicating future revenue potential.
- The company's backlog increased, providing a solid foundation for future performance.
- Leidos successfully managed its cash flow, with a $161 million increase in net cash provided by operating activities compared to the prior year quarter.
- The company repurchased a significant amount of its own stock, indicating confidence in its future prospects.
Negatives
- The Defense Systems segment experienced a slight decrease in operating income.
- Corporate operating loss increased due to higher general and administrative expenses.
- The effective tax rate increased to 23.1% from 20.8% in the prior year due to an increase in unrecognized tax benefits and a reduced benefit in federal research tax credits.
- The company's cash and cash equivalents decreased from $777 million to $633 million.
Risks
- The company's reliance on U.S. government contracts exposes it to changes in government spending and budget priorities.
- International operations expose the company to regulatory and geopolitical risks.
- Ongoing government investigations and reviews could lead to potential penalties and reputational damage.
- The company is subject to ongoing audits by the Defense Contract Audit Agency, which could result in adjustments to contract revenues.
- Changes in international trade policies, including higher tariffs, may increase procurement costs.
Future Outlook
The company anticipates being able to meet its liquidity needs for the next 12 months through cash generated from operations, available cash balances, borrowings from its commercial paper program, and if needed, sales of accounts receivable and borrowings from its revolving credit facility.
Management Comments
- Management believes they have adequately reserved for potential adjustments from audits or reviews of contract costs.
- Management does not believe that outstanding performance guarantees and cross-indemnity agreements will have a material effect on the company's liquidity, capital expenditures, or financial condition.
Industry Context
Leidos operates in the government contracting industry, which is heavily influenced by government spending and budget priorities. The company's performance is tied to the demand for its services in national security, health, and technology sectors. The recent passage of appropriations packages and the release of the President's budget indicate continued government spending in these areas, which could benefit Leidos.
Comparison to Industry Standards
- Leidos's revenue growth of 7.5% year-over-year is a strong result compared to other large government contractors such as General Dynamics (GD) and Lockheed Martin (LMT), which have seen more modest growth in recent quarters.
- The significant increase in operating income, particularly in the Health & Civil segment, suggests that Leidos is effectively managing costs and capitalizing on market opportunities, outperforming some of its peers in terms of profitability.
- The company's backlog of $36.571 billion is a positive indicator of future revenue, and is comparable to other large government contractors with similar long-term contracts.
- Leidos's focus on technology-enabled services and digital modernization aligns with industry trends, positioning it well for future growth compared to companies with less focus on these areas.
Legal Proceedings
- The company is involved in various claims and lawsuits arising in the normal conduct of business, none of which are expected to have a material adverse effect.
- The company is conducting an internal investigation related to international operations and has self-reported to the Department of Justice and the Securities and Exchange Commission.
- The company received a Federal Grand Jury Subpoena related to a criminal investigation by the U.S. Attorneys Office for the Southern District of California.
- The company received a Federal Grand Jury Subpoena in connection with a criminal investigation being conducted by the U.S. Department of Justice Antitrust Division.
Stakeholder Impact
- Shareholders will benefit from the increased profitability and share repurchases.
- Employees may benefit from the company's growth and success.
- Customers will continue to receive services and solutions from the company.
- Suppliers and creditors will continue to engage with the company as a reliable partner.
Next Steps
- The company will continue to evaluate the potential impact of the Pillar Two legislation.
- The company will continue to cooperate with ongoing government investigations and reviews.
- The company will continue to monitor and manage its financial covenants and debt obligations.
Key Dates
| Date | Description |
|---|---|
| March 10, 2023 | Leidos entered into a Credit Agreement providing for a $1.0 billion term loan facility and a $1.0 billion revolving credit facility. |
| February 28, 2023 | Leidos issued and sold $750 million aggregate principal amount of fixed-rate senior notes maturing in March 2033. |
| March 29, 2024 | End of the reporting period for the first quarter of fiscal year 2024. |
| April 23, 2024 | The number of shares issued and outstanding of each of the issuers classes of common stock was 135,211,535 shares. |
| April 30, 2024 | Date of filing of the quarterly report on Form 10-Q. |
Keywords
Leidos, Government Contracts, Defense, Health, Technology, National Security, Digital Modernization, Cybersecurity, Revenue, Net Income, Backlog, Operating Income
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.